At this time, enrollment in the Rare Disease Research Study is limited to United States residents. We currently do not have plans to expand this study to residents of other countries. Research projects like this must be carried out under the supervision of a research ethics committee. In the United States this is called an Institutional Review Board (IRB), which is an independent ethics panel that ensures all research is conducted in accordance with government and ethical guidelines. 23andMe has approval from our IRB to conduct the Rare Disease Research Study only in the United States, and therefore we are not authorized to enroll participants who live outside the United States at this time.